|Videos|January 7, 2014
The Results From a Phase II Study Analyzing First-Line Eribulin Mesylate
Author(s)Kristi McIntyre, MD
Kristi McIntyre, MD, a physician with Texas Oncology, discusses the results of a phase II, multicenter, single-arm study looking at eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer.
Clinical Pearls
Kristi McIntyre, MD, a physician with Texas Oncology, discusses the results of a phase II, multicenter, single-arm study looking at eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer.
- Overall response rate was 29%
- Clinical benefit rate (CR, PR and stable disease) was 52%
- Eribulin does not have hypersensitivity reactions like taxanes
- The study contained both triple-negative and hormone receptor-positive patients
- All metastatic breast cancer patients were HER2-negative
Related Content
Advertisement
